Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,800 Publications201,349 Funding7,267 Clinical research2,831

Loading search results…

Browse

Scholars8,800 Publications201,349 Funding7,267 Clinical research2,831

Filters

Status

Recruiting1,209
Not yet recruiting11
Enrolling by invitation20
Active, not recruiting553
Completed895
Terminated143

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Not reported1,641
Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 4

Investigator

Gail J Roboz49
Parag Goyal36
Harini Sarva33
Shari Lipner30
Manish A Shah28

Show all 50Show fewer

Department

Medicine1,340
Pediatrics239
Obstetrics and Gynecology150
Radiology137
Population Health Sciences121

Show all 26Show fewer

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Show all 50Show fewer

Intervention type

Drug807
Other202
Device190
Biological157
Procedure127
Behavioral83

Sponsor type

WCM (investigator-initiated)1,383
Industry853
Other academic408
NIH107
Unknown41
Cooperative group35

Start date

Has results posted347

Showing 2801–2820 of 2,831 studiesSort:

CompletedInterventional · Phase 3NCT06131437 ↗
Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity
Alpana P. ShuklaPI
Intervention
Drug: Cagrilintide · Drug: Semaglutide · Drug: Tirzepatide
Dates
Nov 2023 – Dec 2025
Sponsor
Novo Nordisk Pharmaceuticals, Inc.
Obesity

Filters

Status

Recruiting1,209
Not yet recruiting11
Enrolling by invitation20
Active, not recruiting553
Completed895
Terminated143

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Not reported1,641
Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 4

Investigator

Gail J Roboz49
Parag Goyal36
Harini Sarva33
Shari Lipner30
Manish A Shah28

Show all 50Show fewer

Department

Medicine1,340
Pediatrics239
Obstetrics and Gynecology150
Radiology137
Population Health Sciences121

Show all 26Show fewer

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Show all 50Show fewer

Intervention type

Drug807
Other202
Device190
Biological157
Procedure127
Behavioral83

Sponsor type

WCM (investigator-initiated)1,383
Industry853
Other academic408
NIH107
Unknown41
Cooperative group35

Start date

Has results posted347

Showing 2801–2820 of 2,831 studiesSort:

CompletedInterventional · Phase 3NCT06131437 ↗
Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity
Alpana P. ShuklaPI
Intervention
Drug: Cagrilintide · Drug: Semaglutide · Drug: Tirzepatide
Dates
Nov 2023 – Dec 2025
Sponsor
Novo Nordisk Pharmaceuticals, Inc.
Obesity

Robert J. Kaner

Alexander Ja-Ho Chou15

Catherine Butkus Small14

Jia Ruan14

Anna Podolanczuk13

Eleni Andreopoulou13

Silvia Chiara Formenti13

Darshana M Dadhania11

Otolaryngology Head and Neck Surgery65

Neurological Surgery59

Cardiothoracic Surgery57

Emergency Medicine48

Anesthesiology46

Pathology and Laboratory Medicine39

Radiation Oncology37

Urology36

Rehabilitation Medicine25

Ophthalmology17

Orthopaedic Surgery11

Systems and Computational Biomedicine11

Genetic Medicine3

Pharmacology3

Biochemistry and Biophysics2

Brain and Mind Research2

Library2

Neoplasms32

Colitis, Ulcerative29

Atrial Fibrillation27

Carcinoma, Non-Small-Cell Lung27

Crohn Disease27

Recurrence27

COVID-1926

Myelodysplastic Syndromes26

Parkinson Disease24

Neoplasm Metastasis23

Obesity23

Colorectal Neoplasms19

HIV Infections19

Hematologic Neoplasms19

Cardiovascular Diseases18

Depression18

Non-alcoholic Fatty Liver Disease16

Overweight15

Lung Neoplasms14

Melanoma14

Cognitive Dysfunction13

Idiopathic Pulmonary Fibrosis13

Inflammatory Bowel Diseases13

Alzheimer Disease12

Leukemia12

Leukemia, Lymphocytic, Chronic, B-Cell12

Lymphoma, Non-Hodgkin12

Primary Myelofibrosis12

Coronary Artery Disease11

Hypertension11

Hypertension, Pulmonary11

Lung Diseases, Interstitial11

Myeloproliferative Disorders11

Pulmonary Arterial Hypertension11

Stroke11

Chronic Pain10

Hemophilia A10

Leukemia, Myelomonocytic, Chronic10

Lymphoma, Follicular10

Lymphoma, Large B-Cell, Diffuse10

Urinary Bladder Neoplasms10

Burkitt Lymphoma9

Fibrosis9

Liver Diseases9

Carcinoma, Renal Cell8

Radiation

Diagnostic test31

Dietary supplement14

Combination product11

Genetic7

Other federal

Completed

Interventional · Not applicable

NCT06146335 ↗

Analysis of Biologic Signatures in Crohn's Patients Undergoing Surgery

Fabrizio MichelassiPI

Intervention: Procedure: Kono-S anastomosis (KSa) · Procedure: Side-to-side anastomosis (SSa)
Dates: Jan 2024 – May 2025
Sponsor: Weill Medical College of Cornell University

Crohn Disease

CompletedObservationalNCT06152276 ↗

SafeHeal Diverting Ileostomy Pivotal Study (SH-SOC23)

Mehraneh Dorna JafariPI

Intervention: Other: Diverting loop ileostomy
Dates: Jan 2024 – Jan 2026
Sponsor: SafeHeal Inc

Colorectal CancerStoma Ileostomy

TerminatedInterventional · Phase 1NCT06163898 ↗

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: Alnuctamab · Drug: Mezigdomide · Drug: Dexamethasone
Dates: Feb 2024 – Jun 2025
Sponsor: Bristol-Myers Squibb Company

Multiple Myeloma

CompletedInterventional · Not applicableNCT06168669 ↗

A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection

Mehraneh Dorna JafariPI

Intervention: Diagnostic test: xBar system
Dates: Mar 2023 – Sep 2025
Sponsor: Exero Medical

Colorectal SurgeryAnastomotic Leak

CompletedInterventional · Phase 1/2NCT06179511 ↗

A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies

Pinkal DesaiPI

Intervention: Drug: AZD9829
Dates: Jan 2024 – Oct 2025
Sponsor: AstraZeneca, PLC

Hematological Malignancies

CompletedObservationalNCT06181669 ↗

Pneumonia Direct Pilot

Matthew William McCarthyPIMarkus PlatePI

Intervention: Diagnostic test: Pathogen and Host Directed testing
Dates: Apr 2024 – Jul 2025
Sponsor: Duke University

Pneumonia, BacterialVentilator Associated Pneumonia

CompletedInterventional · Phase 3NCT06208306 ↗

A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Participated in Either EFC16750 or EFC16819 Clinical Studies

Anthony SmithPI

Intervention: Drug: Itepekimab (SAR440340) · Drug: Placebo
Dates: Jan 2024 – Sep 2026
Sponsor: Sanofi S.A.

Chronic Obstructive Pulmonary Disease

TerminatedInterventional · Not applicableNCT06310720 ↗

You Matter: Using Video Education to Improve Patient Knowledge of Severe Maternal Morbidity Warning Signs in High Risk Populations

Heather LipkindPI

Intervention: Other: Video Education
Dates: May 2024 – Aug 2025
Sponsor: Weill Medical College of Cornell University

Postpartum HemorrhagePostpartum DepressionPostpartum Sepsis+4 more

TerminatedInterventional · Phase 2NCT06317285 ↗

A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Anna PodolanczukPI

Intervention: Drug: GSK3915393 · Drug: Placebo
Dates: Apr 2024 – Oct 2025· Results posted
Sponsor: GlaxoSmithKline

Idiopathic Pulmonary Fibrosis

CompletedExpanded accessNCT06321705 ↗

Expanded Access, Open-Label, Safety Extension Study for Patients That Have Completed Parent Study CS1-003 and Who Are Judged by the Investigator to Benefit From Continued CS1 Treatment

Evelyn M. HornPI

Intervention: Drug: CS1
Dates: Started Nov 2024
Sponsor: Cereno Scientific AB

Pulmonary Arterial Hypertension

TerminatedInterventional · Not applicableNCT06330493 ↗

Prospective Multi-Center Randomized Controlled Trial to Evaluate the Safety and Efficacy of AcoArt Litos Paclitaxel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Versus Non-Coated Standard Balloon Angioplasty for the Treatment of Infrapopliteal Obstructions in Patients With Chronic Limb-Threatening Ischemia

Christopher AgrusaPI

Intervention: Device: PCB · Device: PTA
Dates: Oct 2025 – Aug 2026
Sponsor: Acotec Technologies Limited

Chronic Limb-Threatening Ischemia

CompletedInterventional · Not applicableNCT06404515 ↗

Utilizing Telehealth Group Counseling Sessions to Improve the Process and Delivery of Secondary Preventive Care for Women With Atherosclerotic Cardiovascular Disease

Diala SteitiehPI

Intervention: Other: Telehealth Group Counseling
Dates: Jul 2024 – Nov 2024
Sponsor: Weill Medical College of Cornell University

ASCVDNSTEMISTEMI+5 more

TerminatedInterventional · Phase 3NCT06415344 ↗

A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients With Angelman Syndrome

Srishti NangiaPI

Intervention: Drug: GTX-102
Dates: Jul 2024 – Oct 2026
Sponsor: Ultragenyx Pharmaceutical Inc.

Angelman Syndrome

CompletedInterventional · Not applicableNCT06415942 ↗

Single Arm Clinical Trial of a Novel Smartphone-based Somatic and Psychological Symptom Monitoring and Decision Support Tool for African American and Spanish Speaking Patients in the Near Postpartum Period

Robin B. KalishPI

Intervention: Other: Maternal Outcome Monitoring and Support system
Dates: Dec 2024 – Apr 2026
Sponsor: Columbia University

Maternal DeathMaternal Complication of Pregnancy

CompletedInterventional · Not applicableNCT06452355 ↗

Clinical Trial Designed to Assess the Safety and Effectiveness of the KOKO™ Device In Treating Primary Abnormal Postpartum Uterine Bleeding ("APUB") or Hemorrhage ("PPH")

Daniel W SkupskiPI

Intervention: Device: KOKO Device
Dates: Aug 2024 – Jul 2026
Sponsor: KOKO Medical INC

Postpartum HemorrhageImmediate Postpartum HemorrhageHemorrhage, Postpartum

TerminatedInterventional · Not applicableNCT06466148 ↗

JessieHug Feasibility and Usability Assessment

James M KimPI

Intervention: Device: JessieHug
Dates: Apr 2024 – Feb 2026
Sponsor: Weill Medical College of Cornell University

SIDS

CompletedInterventional · Not applicableNCT06488157 ↗

Adapting and Implementing the I-HoME Intervention in Caregivers of Patients With ADRD

Veerawat PhongtankuelPI

Intervention: Other: I-HoME
Dates: Jul 2024 – May 2025· Results posted
Sponsor: Weill Medical College of Cornell University

Caregiver Burden

CompletedInterventional · Phase 2NCT06560684 ↗

A PHASE 2 CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR-BASED PREP EVALUATING EXTENDED SAFETY, ACCEPTABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS

Grant EllsworthPI

Intervention: Drug: Oral F/TDF Pills · Drug: TFV rectal douche
Dates: Oct 2024 – Jun 2026
Sponsor: National Institute of Allergy & Infectious Diseases

Tenofovir

CompletedInterventional · Not applicableNCT06560970 ↗

A Technology-based Psychosocial Intervention to Support Social Engagement and Well-being in Older Adults With HIV

Sara CzajaPI

Intervention: Behavioral: COPPEhR Intervention · Behavioral: Device-only Control Condition
Dates: Dec 2024 – May 2026
Sponsor: Weill Medical College of Cornell University

HIV Diagnosis

‹ Prev 1 2 3 4 5…138 139 140 141 142 Next ›